Prognosis, follow-up, and supportive care for advanced disease
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
A diagnosis of advanced squamous cell carcinoma (SCC) raises two questions almost immediately: What does this mean for me? and Where do I turn for help? Both deserve honest answers. Advanced SCC is uncommon — the great majority of the roughly 700,000 cutaneous SCCs diagnosed each year in the United States are cured with a single procedure — and most advanced cases are locally advanced rather than spread to distant organs. It is a serious diagnosis, but immunotherapy has made it a far more treatable one than it was a decade ago.
This article walks through how doctors think about prognosis for locally advanced versus metastatic disease, what follow-up looks like after treatment with surgery, radiation, or immunotherapy, how long-term side effects and wound or appearance concerns are managed, and the emotional, practical, and caregiver support that exists alongside medical care.
"Prognosis" is a doctor's best estimate of how a cancer is likely to behave. For advanced SCC it depends on several things: whether the disease is locally advanced or metastatic, whether it has reached the lymph nodes or spread further (the two behave very differently), the tumor's high-risk features such as depth, differentiation, and perineural invasion, your immune status, and how the cancer responds once treatment starts. National estimates suggest that of the hundreds of thousands of cutaneous SCCs diagnosed in the U.S. each year, a small fraction develop nodal metastasis and a smaller fraction still are ultimately fatal — but no single number captures what any one person can expect. Use the framing below for orientation, and ask your own oncology team what it means in your case.
This is a tumor that has grown large or deep, invaded a nerve, or come back repeatedly, so that surgery or radiation can no longer clear it without unacceptable harm. It has not spread to lymph nodes or distant organs.
The outlook here is generally encouraging. In the pivotal trial of cemiplimab, about half of patients with locally advanced disease had significant tumor shrinkage, and pembrolizumab produced a similar response rate. When a response occurs, it frequently lasts more than a year, and extended follow-up of the cemiplimab trial found that the typical duration of response had not even been reached — meaning many people were still responding years later. Some tumors shrink enough that surgery becomes possible again.
Once SCC reaches the lymph nodes, the risk of the cancer spreading further or becoming fatal rises. National estimates put the number of Americans who develop nodal metastasis from cutaneous SCC each year at roughly 6,000 to 13,000, out of hundreds of thousands of new SCC diagnoses — a small share of all cases, but a much higher-risk group than SCC overall. Spread to distant organs (lungs, liver, bone, or distant nodes) is less common still and is harder to control.
Even so, the same PD-1 immunotherapy drugs used for locally advanced disease produce responses in roughly a third to half of patients with recurrent or metastatic SCC, and non-immunotherapy options — chemotherapy, EGFR-targeted therapy, or a clinical trial — remain available afterward. Many people live for extended periods with the disease managed as a chronic condition, adjusting treatment as circumstances change.
A note on statistics: because cutaneous SCC has historically been excluded from national cancer registries, published outcome figures come from estimates and individual institution studies rather than a single national database, and most predate widespread use of immunotherapy. They rarely reflect what a person facing advanced SCC today can expect. Your care team's individualized estimate, informed by your specific pathology and response to treatment, is more meaningful than any general number.
After surgery, radiation, or systemic therapy for advanced SCC, follow-up is close at first and then spaced out if the cancer stays controlled. A typical schedule looks something like this, tailored to your situation:
Tell your team promptly about any new lump, non-healing sore, numbness or weakness near the old tumor site or along a treated nerve, or a swollen lymph node. Between visits, keep a simple written record of symptoms and questions to bring with you.
Some people stay on immunotherapy for up to two years, and its immune-related side effects — fatigue, skin rash, joint aches, and inflammation of the thyroid, gut, liver, or lungs — can appear at any point during treatment or even after it ends. These are usually manageable when caught early, and managing them well is part of staying on effective treatment.
The companion article on managing immunotherapy side effects covers these in more detail.
Advanced SCC often affects the face, ears, scalp, or hands — areas that are hard to hide — and surgery or radiation can leave a wound, a surgical defect, or a visible change. This is one of the most difficult parts of the experience, and there is real help for it:
Research on facial skin cancer surgery finds that appearance-related distress is often highest right after treatment and tends to ease over the following months, and that people with a history of anxiety or depression benefit most from proactive support. If the change is weighing on you, say so — it is a medical concern, not vanity.
Living with an advanced skin cancer can feel isolating, especially when friends assume "skin cancer" always means something minor. Anxiety about scans, low mood, and strain on relationships are common and treatable.
Palliative care — also called supportive care — is specialized care focused on relief from symptoms, side effects, and stress at any stage of a serious illness. It is not the same as hospice, and it does not mean giving up on treatment. It is delivered alongside cancer treatment, and studies show it can improve quality of life and mood.
A palliative care team can help with:
You can ask for a palliative care referral at any point — earlier is often better. If the cancer is advanced and treatment is no longer helping, hospice care provides comfort-focused support at home or in a facility.
The partner, adult child, or friend helping with dressings, appointments, and daily life carries a real load. Caregivers do better — and can give better care — when they are supported too.
Advanced squamous cell carcinoma is serious, but for most people it is locally advanced, treatable, and increasingly controllable for the long term. Immunotherapy has changed the outlook substantially, and even nodal or metastatic disease — though harder to cure — can often be managed as a chronic condition with the tools now available.
Just as important as the medical treatment is the web of support around it: close follow-up, thoughtful management of long-term side effects, reconstruction and appearance care, mental health and peer support, palliative care, and help for the people caring for you. Ask for these things early. You do not have to navigate advanced SCC alone.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis, prognosis, and treatment plan.
Chat with our AI guide for information about living with advanced squamous cell carcinoma
Chat with the Navigator